Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia Limited (Lilly) have signed a ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

TOKYO (Kyodo) -- A single course of newly approved Alzheimer's drug donanemab-azbt ... The drug developed by U.S.

US pharmaceutical company Eli Lilly brings Memory Cafe to its booth at the ongoing 7th CIIE in collaboration with the ...

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

The signing of a Memorandum of Understanding (MoU) between King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia Limi ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.